ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2674

The Association between the Extent of Skin Thickness and Organ Involvement, Function and Quality of Life in Early Diffuse Cutaneous Systemic Sclerosis

Janet E. Pope1, Murray Baron2, Tatiana Nevskaya3, Carl Baxter4 and Dena Ramey5, 1Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, 3Rheumatology Division, St. Joseph’s Health Care London, London, ON, Canada, 4Global Outcomes Research, MSD Ltd, Hoddesdon, United Kingdom, 5Epidemiology, Merck & Co., Upper Gwynedd, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To estimate whether severity of skin thickness is associated with disease severity, function, quality of life (QoL) and progression of internal organ involvement over 12 months in early diffuse cutaneous systemic sclerosis (dcSSc).

Methods: We included dcSSc patients from the Canadian Scleroderma Research Group (CSRG) database with disease duration of ≤5 years from the onset of first non-Raynaud’s symptom at initial visit and 1-year follow-up (FU) . We assessed severity of skin involvement with the modified Rodnan skin score (mRSS); internal organ involvement with the Medsger organ severity scores; global measures of disease status with patient- and physician-reported 11 point numerical rating scales (NRS); disease activity with the European Scleroderma Study Group (EScSG) activity index; function with the HAQ and S-HAQ 11 point NRS scales; and QoL with the SF-36. Bivariate, ANOVA, linear and logistic regression analyses were used to study the associations between mRSS and outcomes, adjusted for potential confounding factors.

Results: At baseline (N=204, 74% female, mean age 51±12 yrs, disease duration 2.1±1.3 yrs), higher mRSS was significantly associated with worse total disease severity (Medsger’s score without skin component, physician and patient global NRS, S-HAQ overall disease rating), functional disability (HAQ-DI) and worse QoL (SF-36 PCS) (p<0.0001 for all). Higher mRSS was also associated with the presence and severity of tendon involvement (p<0.0001), severity of gastrointestinal disease (p=0.021), S-HAQ digital ulcer severity (p=0.008) and S-HAQ intestinal problems (p=0.008) by adjusted regression analysis.

At 1-year FU visit (N=174, 74% female, mean age 51±12 yrs, disease duration 2.1±1.3 yrs) we found a significant reduction in mRSS (22.51±9.27 vs 19.42±10.45, p=0.006). There was also a decrease in disease activity by both EScSG-activity index (3.06±1.8 vs 2.41±1.8, p=0.003) and physician-assessed disease activity on NRS scale (4.61±2.37 vs 3.52±2.17, p<0.0001). There were no changes in other measures of disease characteristics.

We also examined the associations between baseline mRSS and outcomes at 1-year FU visit using adjusted regression analysis. Higher baseline mRSS was associated with worse HAQ-DI (p=0.0001) and SF-36 PCS (p=0.0001), higher total Medsger’s severity score (p=0.014), physician-assessed disease damage (p=0.001), severity (p=0.008) and joint involvement (p=0.0001) at FU. Baseline mRSS was not associated with presence/severity of kidney, lung or heart disease at baseline or 1-year FU visit, nor predictive of new/progression of organ involvement over time.

Conclusion: Greater skin involvement at baseline was associated with worse joint and GI involvement, worse function and QoL. Baseline mRSS also predicted function, severity of joint involvement and QoL at 1-year FU. No association between skin involvement and burden of other organ-based complications was found, but follow-up was limited to 1-year in this analysis.


Disclosure: J. E. Pope, AbbVie, Amgen, Bayer, BMS, Celtrion, Eli Lilly and Company, Merck, Novartis, Pfizer, Roche, UCB, 5,Amgen, Bayer, BMS, GSK, Merck, Novartis, Pfizer, Roche, UCB, 2; M. Baron, None; T. Nevskaya, None; C. Baxter, MSD Ltd, 3; D. Ramey, Merck and Co., Inc., 3.

To cite this abstract in AMA style:

Pope JE, Baron M, Nevskaya T, Baxter C, Ramey D. The Association between the Extent of Skin Thickness and Organ Involvement, Function and Quality of Life in Early Diffuse Cutaneous Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-association-between-the-extent-of-skin-thickness-and-organ-involvement-function-and-quality-of-life-in-early-diffuse-cutaneous-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-the-extent-of-skin-thickness-and-organ-involvement-function-and-quality-of-life-in-early-diffuse-cutaneous-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology